Protalix BioTherapeutics Reports Strong Q2 2025 Results with Revenue Surge and Strategic Leadership Changes
Protalix BioTherapeutics Inc. reports a 16% increase in revenues to $15.4 million in Q2 2025, driven by strong sales of Elfabrio in the Fabry disease market.
- Protalix BioTherapeutics Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read